Efruxifermin
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT05039450 | Jul 2021 → Aug 2023 overdue | metabolic dysfunction-associated steatohepatitis | Akero Therapeutics, Inc | Active not recruiting | Missed primary |
| Phase 2 | NCT04767529 | Feb 2021 → May 2024 | metabolic dysfunction-associated steatohepatitis | Akero Therapeutics, Inc | Completed | Met primary |
| Phase 2 | NCT03976401 | May 2019 → Feb 2021 | metabolic dysfunction-associated steatohepatitis | Akero Therapeutics, Inc | Completed | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT06528314 | Sep 2024 → Feb 2030 expected | metabolic dysfunction-associated steatohepatitis | Akero Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT06215716 | Dec 2023 → Feb 2033 expected | metabolic dysfunction-associated steatohepatitis | Akero Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT06161571 | Nov 2023 → Mar 2026 overdue | metabolic dysfunction-associated steatohepatitis | Akero Therapeutics, Inc | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01856881 Comparator | Mar 2013 → Nov 2014 | type 2 diabetes mellitus | Amgen | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01492465 Comparator | Nov 2011 → Jul 2012 | type 2 diabetes mellitus | Amgen | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Efruxifermin | “This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4 NASH.” NCT03976401 ↗5“This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.” NCT05039450 ↗ |
| Known as | AKR-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594389 ↗ |
| Known as | AMG 876 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01492465 ↗ |
| Known as | EFX | “This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4 NASH.” NCT03976401 ↗3“This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.” NCT05039450 ↗ “This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.” NCT06528314 ↗ “This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study” NCT06215716 ↗ |
| Modality | Protein / enzyme biologic | “We assessed the safety and efficacy of efruxifermin, a long-acting Fc-FGF21 fusion protein, for the treatment of NASH.” PMID 34239138 ↗ Jul 2021 |
| Route | Subcutaneous | “administered SC” NCT01492465 ↗ |